To the Editors:

Screening for diabetes mellitus in pregnancy

We read with interest the research letter on the above subject which appeared in the Ceylon Medical Journal 2002; 47: 38–39, and like to clarify certain points.

Gestational diabetes mellitus (GDM) is a well known entity which is diagnosed on 75 g oral glucose tolerance test and is a defined blood glucose criteria [1]. The other abnormality of carbohydrate metabolism which occurs during pregnancy is impaired glucose tolerance which has almost the same impact as GDM [2].

We do not agree with their statement, “In high risk populations such as Asians, the World Health Organization (WHO) advocates screening during the first trimester to detect previously undiagnosed diabetes and a formal oral glucose tolerance test between 24 and 28 weeks of gestation to diagnose gestational diabetes mellitus”. One of the principal criteria for screening as defined by the WHO is that the test should be applicable to the whole population. Universal screening for GDM is superior to risk factor based screening, in detecting more cases, facilitating early diagnosis and ensuring improved pregnancy outcome [3].

Two types of screening tests are being done in most of the specialised antenatal clinics worldwide to detect GDM. They are the 2-hour post-prandial blood glucose and the 50 g 1-hour glucose challenge test. When interpreting the 50 g 1-hour glucose challenge test the threshold for further testing may be chosen based on the goal of the screening program, either to maximise sensitivity at the expense of more diagnostic testing by using a 130 mg/dL cutoff or to increase specificity at the cost of some sensitivity by using a 140 mg/dL cutoff [4]. Ideally the screening test should be done at 16 weeks and repeated in the third trimester to identify late onset of GDM and a positive test should be followed by a 75 g oral glucose tolerance test. We are now doing research to find out which screening test is better to detect GDM in our population.

References

Hiran Samarage, Senior Lecturer and Obstetrician and Gynaecologist, and Sanjeewa Padumadasa, Registrar, Professorial Obstetrics and Gynaecology Unit, Teaching Hospital, Galle, Sri Lanka.

To the Editors:

Neonatal jaundice due to maternal ingestion of “veniwelgata”?

CN was born after an emergency caesarean section at term and weighed 3.5 kg. There were no problems at birth. She was the second child in the family. On the fourth day she was noticed to be jaundiced and had a serum bilirubin level of 292 μmol/L with an indirect component of 216 μmol/L. The jaundice persisted for about 5 weeks and reached a peak level of 432 μmol/L (indirect 414 μmol/L) on the 30th day. The jaundice was managed conservatively with minimal intervention. The baby was breast-fed and continued to thrive well.

The haemoglobin ranged from 16.5 g/dL to 11.8 g/dL during this period. The baby’s blood group was O+ve and the mother was B+ve. The Coomb test was negative, serum TSH level was normal and urine culture sterile. The blood film was reported as normal. G6PD enzyme assay was in the normal range. Ultrasound examination of the abdomen was reported as normal.

As there was no apparent cause for the jaundice, some searching questions were asked from the parents. The mother had ingested a decoction of veniwelgata (Coscinium fenestratum) prepared by boiling 50 g of the herb and ingesting 250 ml of the decoction, twice or thrice daily, throughout pregnancy and for 1 month after delivery. Veniwelgata is a bitter tonic and its decoction is used as a remedy for, or to prevent tetanus. The root has antiseptic properties and is often used for dressing wounds and ulcers [1].